We'd also like the community to continue to support the other families impacted by this tragic accident. Our goal this weekend was to get Jason out of the water for closure and we did that. We're very appreciative, " said family spokesperson Ryan Bartlett. Less than a mile from the Who So Ever Will Community Church, members opened their doors for loved ones as well as search crews to take a break and have a meal. Weight Watchers of The Bahamas is a Franchise of Weight Watchers International, Inc. and has been operating since January 12, 1988. If you're looking for a successful, safe and exciting way to lose weight, delivered with an understanding of your individual weight loss challenges, look no further Weight Watchers Of The Bahamas is the weight loss service for you! The 1920s burberry resides in the popular imagination as a decade where some enjoyed untamed fun and hedonism. This spirit was reflected in the upper class youths dubbed the 'Bright Young Things' who, as conjured up by F. Scott Fitzgerald's novels, danced to imported American jazz music, attended a host of parties and drove cars. This indicates to us that while it is reasonable to assume that the failure of burberry Vynfinit to meet its primary endpoint in PROC would most likely have a negative impact on its chances for the same indication in the EU, its chances of an approval for NSCLC could be assumed to be only slightly lower than burberry before. Indeed, many of the brokers that lowered price targets on PROC following Friday's announcement would agree with our assessment, with Chardan Capital Markets, RBC Capital Markets and Brean Capital, all indicating as such in their assessments, lowering their price targets to $26, $20 and $22 respectively, still about 200% above its closing price on Friday. Besides PROC and NSCLC, Endocyte is also testing Vynfinit in a third indication, triple negative breast cancer, and is expected to commence a Phase 2 trial sometime in Q2'14. Furthermore, the market size for NSCLC is estimated to be much larger than the market size for the failed PROC indication, and the overall revenue for Vynfinit was estimated earlier last year by Brean Capital at $2 bill. in 2026, only $250 mill. of that being accounted for by the failed PROC indication. Assuming even that the burberry probability for success in the other indications fell by about a third due to the failure in PROC, it would seem that the overall revenue target in 2026 would only burberry fall by about 40% to $1.2 bill. based on Brean Capital's earlier revenue target of $2 bill.